← back to search

Zachary S. Wallace

Amgen (United States) · US
Area of research
Infectious Diseases · Rheumatology
Research interest
Research interests include COVID-19 Clinical Research Studies, IgG4-Related and Inflammatory Diseases, Vasculitis and related conditions, and Rheumatoid Arthritis Research and Therapies.
h-index
57
citations
15,473
works
297
NIH funding
primary concept
Medicine
email

Recent publications

Inebilizumab for Treatment of IgG4-Related Disease
New England Journal of Medicine 2024cited by 103position: middledoi
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Science Translational Medicine 2024cited by 95position: middledoi
Emerging SARS-CoV-2 Resistance After Antiviral Treatment
JAMA Network Open 2024cited by 41position: middledoi
T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19
Science Translational Medicine 2023cited by 47position: middledoi
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Annals of the Rheumatic Diseases 2023cited by 18position: middledoi
Impact of Risk Factors on <scp>COVID</scp>‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the <scp>COVID</scp>‐19 Global Rheumatology Alliance Registry
Arthritis Care & Research 2023cited by 12position: middledoi
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Annals of the Rheumatic Diseases 2022cited by 91position: middledoi
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Lara D. Veeken 2022cited by 71position: middledoi
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
RMD Open 2022cited by 51position: middledoi
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
RMD Open 2022cited by 43position: middledoi
Association Between Race/Ethnicity and <scp>COVID</scp>‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the <scp>COVID</scp>‐19 Global Rheumatology Alliance
Arthritis Care & Research 2022cited by 22position: middledoi
Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey
Rheumatology Advances in Practice 2022cited by 19position: middledoi
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
The Lancet Rheumatology 2022cited by 19position: middledoi
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
RMD Open 2022cited by 13position: middledoi
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Annals of the Rheumatic Diseases 2021cited by 690position: middledoi
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Annals of the Rheumatic Diseases 2021cited by 241position: middledoi
<scp>SARS</scp>–<scp>CoV</scp>‐2 Infection and <scp>COVID</scp>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
Arthritis & Rheumatology 2021cited by 183position: middledoi
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
RMD Open 2021cited by 169position: middledoi
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
JAMA Network Open 2021cited by 116position: middledoi
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases
The Lancet Rheumatology 2021cited by 54position: middledoi
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
The Lancet Rheumatology 2021cited by 50position: middledoi
ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry
The Journal of Rheumatology 2021cited by 13position: firstdoi
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Annals of the Rheumatic Diseases 2020cited by 1,177position: middledoi
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
The Lancet Rheumatology 2020cited by 219position: middledoi
Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Arthritis & Rheumatology 2020cited by 94position: middledoi
Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐Analysis
Arthritis & Rheumatology 2020cited by 80position: middledoi
SARS CoV-2 infection among patients using immunomodulatory therapies
Annals of the Rheumatic Diseases 2020cited by 32position: middledoi
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
Annals of the Rheumatic Diseases 2019cited by 729position: firstdoi
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease
Arthritis & Rheumatology 2019cited by 634position: firstdoi
Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts
Annals of the Rheumatic Diseases 2019cited by 402position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

John H. Stone · Harvard University10 papers (2014–2021)Hyon K. Choi · Boston University7 papers (2015–2021)Vikram Deshpande · Harvard University6 papers (2014–2016)Vinay S. Mahajan · Ragon Institute of MGH, MIT and Harvard5 papers (2014–2016)Shiv Pillai · Harvard University5 papers (2014–2016)Hamid Mattoo · Center for Cancer Research5 papers (2014–2016)Cory A. Perugino · Harvard University4 papers (2019–2024)Mollie N. Carruthers · Research Canada4 papers (2014–2016)Emanuel Della‐Torre · Center for Cancer Research4 papers (2014–2024) · 4 papers (2014–2016)Arezou Khosroshahi · Emory University4 papers (2015–2024)N. Schleinitz · Assistance Publique Hôpitaux de Marseille3 papers (2019–2024)Rebecca Grainger · University of Otago3 papers (2020–2022)Suresh T. Chari · The University of Texas MD Anderson Cancer Center3 papers (2015–2019)Jean W. Liew · Boston University3 papers (2020–2022) · 3 papers (2019–2024)Philip C. Robinson · Medical College of Wisconsin3 papers (2020–2022)Ray Naden · McMaster University3 papers (2019–2019) · 3 papers (2019–2024)Kazuichi Okazaki · Kansai Medical University3 papers (2019–2024)